Navigation Links
DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Company's Melanoma Advisory Board
Date:3/5/2008

LA JOLLA, Calif., March 5 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Allan C. Halpern, MD, has joined DermTech's Melanoma Advisory Board. Dr. Halpern is Chief of Dermatology at Memorial Sloan-Kettering Cancer Center and widely recognized as an expert in the early detection and management of melanoma in high-risk individuals.

"We are delighted and honored to welcome Dr. Halpern to our Melanoma Advisory Board," said George Schwartz, CEO, DermTech. "Dr. Halpern is a world leader in the area of melanoma and strategies for improved diagnosis and prevention of this disease that, if identified early, has an extremely high cure rate. DermTech will clearly benefit from his significant experience as we move toward clinical trials of our novel, non-invasive molecular diagnostic product for melanoma early detection."

"I am looking forward to working with the company and the outstanding panel of dermatologists and melanoma experts already on this advisory board," said Allan Halpern, MD. Other Melanoma Advisory Board members include: Boris Bastian, MD, David Polsky, MD, PhD, and Harold S. Rabinovitz, MD.

Allan Halpern, MD, is a board-certified internist and dermatologist. In addition to his role as Chief of Dermatology at MSKCC, he is co-leader of the Center's Melanoma Disease Management Team, which incorporates the expertise of doctors in surgery, medical oncology, clinical immunology, dermatology, pathology, and radiation oncology to diagnose and treat melanoma. He pioneered the use of digital whole-body photography to assist in the detection of changing moles in patients with dysplastic nevi (large, irregular colored or shaped moles). Currently, his research is focused on epidemiologic (population-based) studies with a subset of this research devoted to the study of the genetic and environmental factors that influence the development of moles in children and adolescents. Dr. Halpern received his medical degree from the Albert Einstein College of Medicine in New York and completed his Dermatology residency at the Hospital of the University of Pennsylvania. He has presented and published extensively on melanoma detection.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens obtained from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR(TM) and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information visit http://www.dermtech.com.

Contacts:

DermTech

George Schwartz

CEO

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Radlink Names Allan Christensen Vice President of Technical Services
2. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
3. WorldHeart Appoints David Pellone Chief Financial Officer
4. Mediware Names Thomas K. Mann Chief Executive Officer
5. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
6. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
7. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
8. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
9. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
10. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: